- Home
- VRTX vs INTU Comparison
VRTX vs INTU Comparison
Compare VRTX & INTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRTX | INTU |
|---|---|---|
| Founded | 1989 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer Software: Prepackaged Software |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 101.4B |
| IPO Year | 2006 | 1996 |
Fundamental Metrics
Financial Performance| Metric | VRTX | INTU |
|---|---|---|
| Price | $441.69 | $392.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 21 |
| Target Price | $539.69 | ★ $692.71 |
| AVG Volume (30 Days) | 1.2M | ★ 3.0M |
| Earning Date | 05-04-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 1.24% |
| EPS Growth | ★ 836.54 | 31.06 |
| EPS | ★ 15.32 | 4.06 |
| Revenue | $2,488,652,000.00 | ★ $18,831,000,000.00 |
| Revenue This Year | $10.81 | $15.03 |
| Revenue Next Year | $10.41 | $12.41 |
| P/E Ratio | ★ $28.46 | $95.22 |
| Revenue Growth | ★ 46.20 | 15.63 |
| 52 Week Low | $362.50 | $342.11 |
| 52 Week High | $510.77 | $813.48 |
Technical Indicators
Market Signals| Indicator | VRTX | INTU |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 43.96 |
| Support Level | $427.52 | $345.55 |
| Resistance Level | $442.22 | $478.99 |
| Average True Range (ATR) | 10.31 | 17.38 |
| MACD | 0.72 | -1.04 |
| Stochastic Oscillator | 57.31 | 53.08 |
Price Performance
Historical ComparisonAbout VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.